分散和杂交临床试验have been prevalent for years, yet sponsors have struggled to execute these patient-centric trials effectively. Explore the perceived barriers and how you can make these models a feasible option for the future.Read the whitepaper
During COVID-19 the levels of remote monitoring increased due to site closures and safety reasons. Now is the time to learn from that experience and review whether a hybrid model of remote monitoring and centralised monitoring is the way forward for some trials. Learn best practices in analysing and assessing risk in clinical monitoring and how to remain agile adapting to environmental conditions and therapeutic focus.Read the whitepaper
Understand how to implementwearable devicesand harness digital endpoints in clinical trials:
The collection of real-time data in a home setting can give sponsors and trial managers greater visibility and assurance around GCP and protocol compliance.
Exploring the patient perspective from different angles.
Steps to implement security into mHealth development.
Patient engagement is permeating all spheres of the healthcare ecosystem.
Project teams need to be challenged constantly to justify the study procedures and eligibility criteria they are proposing.
How can pharma improve the patient centricity of its trials during COVID-19 and beyond?
Decentralised and hybrid trials bring a wide range of benefits to the patient and the sponsor. Find out more about the range of decentralised and hybrid trials services available from ICON.阅读更多关于图标服务bob体育手机的更多信息